Cryo-Cell International, Inc. (CCEL)
NYSEAMERICAN: CCEL · Real-Time Price · USD
3.630
-0.350 (-8.79%)
Dec 2, 2025, 3:09 PM EST - Market open
Cryo-Cell International Market Cap
Cryo-Cell International has a market cap or net worth of $29.24 million as of December 2, 2025. Its market cap has decreased by -61.12% in one year.
Market Cap
29.24M
Enterprise Value
41.44M
1-Year Change
-61.12%
Ranking
Category
Stock Price
$3.63
Market Cap Chart
Since December 1, 1998, Cryo-Cell International's market cap has increased from $21.70M to $29.24M, an increase of 34.75%. That is a compound annual growth rate of 1.11%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 28, 2025 | 34.60M | -42.04% |
| Dec 31, 2024 | 59.70M | 25.42% |
| Dec 29, 2023 | 47.60M | 32.22% |
| Dec 30, 2022 | 36.00M | -63.60% |
| Dec 31, 2021 | 98.90M | 70.22% |
| Dec 31, 2020 | 58.10M | 4.50% |
| Dec 31, 2019 | 55.60M | -4.96% |
| Dec 31, 2018 | 58.50M | -14.85% |
| Dec 29, 2017 | 68.70M | 121.61% |
| Dec 30, 2016 | 31.00M | 6.90% |
| Dec 31, 2015 | 29.00M | 21.34% |
| Dec 31, 2014 | 23.90M | 20.10% |
| Dec 31, 2013 | 19.90M | -14.96% |
| Dec 31, 2012 | 23.40M | -0.43% |
| Dec 30, 2011 | 23.50M | -16.67% |
| Dec 31, 2010 | 28.20M | 34.93% |
| Dec 31, 2009 | 20.90M | 326.53% |
| Dec 31, 2008 | 4.90M | -46.74% |
| Dec 31, 2007 | 9.20M | -65.28% |
| Dec 29, 2006 | 26.50M | -32.91% |
| Dec 30, 2005 | 39.50M | -19.22% |
| Dec 31, 2004 | 48.90M | 431.52% |
| Dec 31, 2003 | 9.20M | -50.27% |
| Dec 31, 2002 | 18.50M | -65.80% |
| Dec 31, 2001 | 54.10M | 132.19% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 962.96B |
| Johnson & Johnson | 498.53B |
| AbbVie | 402.43B |
| UnitedHealth Group | 298.72B |
| AstraZeneca | 286.85B |
| Merck & Co. | 260.19B |
| Novartis AG | 249.40B |
| Abbott Laboratories | 224.14B |